This Article Abstract Figures Only Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rossi, A. Articles by Seward, J. B. Search for Related Content PubMed PubMed Citation Articles by Rossi, A. Articles by Seward, J. B.

ARTICLE

Natriuretic peptide levels in atrial fibrillation

A prospective hormonal and Doppler-echocardiographic study

Andrea Rossi, MD^*, Maurice Enriquez-Sarano, MD, FACC^*, John C. Burnett, Jr., MD^*, Amir Lerman, MD^*, Martin D. Abel, MD and James B. Seward, MD, FACC^*

^* Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
Division of Cardiovascular/Thoracic Anesthesia, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA

Manuscript received July 29, 1999; revised manuscript received November 5, 1999, accepted December 15, 1999.

Reprint requests and correspondence: Dr. Maurice Enriquez-Sarano, Mayo Clinic, 200 First St. SW, Rochester, Minnesota 55905

	Abstract

Top Abstract Methods Results Discussion Conclusions References

 
OBJECTIVES

The objective was to determine the independent association between atrial fibrillation (A-Fib) and activation of natriuretic peptides.

BACKGROUND

The association of A-Fib with activation of N-terminal atrial and brain natriuretic peptides (N-ANPs and BNPs, respectively) is uncertain but of great importance for the diagnostic utilization of natriuretic peptides. This uncertainty is related to the lack of appropriate controls, with left ventricular (LV) and atrial overload similar to A-Fib.

METHODS

We prospectively measured N-terminal atrial and BNPs and endothelin-1 levels in 100 patients and 14 age- and gender-matched control subjects. The 32 patients with A-Fib were compared with 68 patients in sinus rhythm and similar LV and atrial overload (due to mitral regurgitation or LV dysfunction) measured simultaneously with hormonal levels with comprehensive Doppler echocardiography.

RESULTS

Patients with A-Fib compared with those in sinus rhythm had similar symptoms, comorbid conditions, cardioactive medications, pulmonary pressure, left atrial volume, and LV ejection fraction and filling characteristics but demonstrated higher N-ANP levels (2,613 ± 1,681 vs. 1,654 ± 1,323 pg/ml, p = 0.007) even after adjustment for the underlying cardiac disease (p < 0.0001). Conversely, BNP levels were similar in both groups (165 ± 163 vs. 160 ± 269 pg/ml, p = 0.9). In multivariate analysis, a higher N-ANP level was associated with A-Fib (p = 0.0003), symptom class (p < 0.0001) and endothelin-1 level (p = 0.032) independently of left atrial volume and LV ejection fraction. Conversely, BNP showed no independent association with and was most strongly associated with LV ejection fraction (p < 0.0001).

CONCLUSIONS

Atrial fibrillation is an independent determinant of higher N-ANP levels and blurs its association with LV dysfunction. Conversely, the BNP is not independently associated with A-Fib and is strongly determined by LV dysfunction, for which it is an independent marker.

Abbreviations and Acronyms   A-Fib = atrial fibrillation   ANOVA = analysis of variance   ANP = atrial natriuretic peptide   BNP = brain natriuretic peptide   CHF = congestive heart failure   EF = ejection fraction   LA = left atrium, left atrial   LV = left ventricle, left ventricular   N-ANP = N-terminal ANP   NYHA = New York Heart Association

Because CHF is frequent (8) and associated with high mortality (8,9), early treatment is essential, emphasizing the need for early diagnosis before the occurrence of overt heart failure (10). This, in turn, has raised the hope that the hormonal activation associated with heart failure (10), in particular that of natriuretic peptides, could be used for the early diagnosis of left ventricular (LV) dysfunction (11). N-terminal ANP (N-ANP), which has a prolonged half-life (12), and BNP levels are increased in patients with LV dysfunction (11,13–15), even if asymptomatic (11). However, the diagnostic use of these hormonal levels remains controversial (16), in particular because other cardiac diseases associated with aging (17) and atrial overload (18) may also result in their activation.

Atrial fibrillation (A-Fib) is a frequent disease among the elderly, who represent the same population affected by CHF (19). Previous studies have suggested that C-terminal ANP levels are elevated in patients with A-Fib (20,21). Regarding N-ANP or BNP levels, specific information has been limited or lacking (22,23), and A-Fib was either acute (23) or associated mostly with concomitant left-sided heart disease, such as cardiomyopathy or mitral stenosis (22,24,25). Therefore, it is unclear whether chronic A-Fib in and by itself, rather than left atrial (LA) enlargement (18), hemodynamic impairment (23) or other hormonal alteration, can result in elevation of N-ANP or BNP levels. An independent association would have major implications for the utilization of hormonal levels in the diagnosis of LV dysfunction and would raise important questions regarding the significance of hormonal activation in A-Fib.

To analyze the intrinsic effect of A-Fib on natriuretic peptides, it is essential to compare patients with A-Fib and sinus rhythm with similar clinical characteristics and ranges of atrial volume, hemodynamics and LV function. Therefore, natriuretic peptide levels and comprehensive Doppler echocardiography were obtained prospectively and simultaneously in patients with LA overload in sinus rhythm or A-Fib to verify the hypothesis that A-Fib is a major determinant of natriuretic peptide levels, independently of LA volume, LV function or hemodynamic alterations.

	Methods

Top Abstract Methods Results Discussion Conclusions References

 
The patients were enrolled prospectively. Patient inclusion criteria were 1) sinus rhythm with either primary (i.e., not caused by valve or pericardial disease or acute myocardial infarction) LV dysfunction (ejection fraction [EF] <50%) or organic mitral regurgitation (due to intrinsic valvular disease) or 2) chronic A-Fib, idiopathic (lone) or due either to primary LV dysfunction or to organic mitral regurgitation. The duration of overt A-Fib ranged from six months to 13 years (mean, 49 ± 50 months). The underlying cardiac disease was defined on the basis of history, clinical examination and Doppler echocardiography. The methodologic inclusion criteria were 1) comprehensive quantitative Doppler echocardiographic assessment and 2) simultaneous venous blood sampling for measuring hormonal levels. Exclusion criteria were as follows: 1) relatively recent onset (<6 months) of A-Fib; 2) high heart rate (>120 beats/min); 3) associated aortic valve disease, pericardial disease or congenital heart disease as determined by Doppler echocardiography; and 4) known major comorbid condition such as stroke or extensive atherosclerosis or renal, liver, or respiratory failure or malignancy. No exclusions were made on the basis of gender, race, age, degree of mitral regurgitation or degree of hemodynamic impairment. A total of 100 patients were enrolled in the study. These patients were referred to the echocardiographic laboratory for systolic murmur or history of mitral regurgitation (n = 58), for heart failure or LV dysfunction (n = 24) or for A-Fib (n = 18). The mean age was 70 ± 8 years, and 37% were female. The symptoms of heart failure (according to the New York Heart Association [NYHA] class), the treatment received and associated comorbid conditions were noted. Fourteen gender, and age-matched subjects in sinus rhythm, with no history of heart disease and entirely normal echocardiographic findings referred to the echocardiographic laboratory to rule out pericardial disease or for systolic murmurs, were enrolled as a control group.

Echocardiographic study.   All patients had a complete two-dimensional echocardiographic and Doppler study that used multiple windows, as previously described (26).

The quantitative Doppler study was performed as previously described (27,28), and mitral and aortic stroke volumes were calculated. At least three measurements of each variable were averaged (six in patients with A-Fib). Cardiac output and index were calculated using the aortic stroke volume (27). Both mitral and aortic stroke volumes were used to calculate the mitral regurgitant volume and regurgitant fraction in all patients (28). In the presence of notable mitral regurgitation, the regurgitant volume was also measured by the proximal isovelocity surface area method (29). The measurement of regurgitant volume by these two methods showed close correlation (r = 0.98; p < 0.0001; standard error of the estimate, 8.5 ml). In our laboratory interobserver and intraobserver variabilities for regurgitant volume are low, 3.9 ± 4.8 and 6.0 ± 3.8 ml, respectively. Pulmonary artery systolic pressure was measured using the tricuspid regurgitant jet velocity (30).

Left atrial volume was measured at end-systole (largest atrial volume) with the use of two orthogonal apical views (31). Right atrial volume was measured at end-systole with a single plane method from the apical view. Left ventricular filling was assessed by the E-velocity and deceleration time obtained by pulsed-wave Doppler. Left ventricular end-systolic and end-diastolic volumes were measured by using the biapical Simpson’s rule, as recommended by the American Society of Echocardiography (32), allowing calculation of the LV EF. The total LV stroke volume calculated by this method and by the Doppler method showed close correlation (r = 0.98; p < 0.0001; standard error of the estimate, 5.9 ml).

Blood sampling.   At the end of the echocardiographic examination and, thus, after the patient had been in a supine position for at least 30 min, a blood sample was drawn from a peripheral vein into edetic acid-coated tubes containing chilled potassium, immediately placed on ice and centrifuged at 2,500 rpm at 4°C. Plasma was separated and stored at –20°C. The N-ANP level was measured after extraction, using a polyclonal antibody to human ANP 26–55. The recovery is 86% and the intra-assay and interassay variabilities are 6% and 9%, respectively. There is no cross-reactivity with C-terminal ANP or BNP. The BNP level was measured using an assay with double antibody-coated beads to human BNP. The intra-assay and interassay variabilities are both 11%. The endothelin-1 level was measured after extraction using a polyclonal rabbit antiendothelin-1 antibody. The recovery is 81% and intra-assay and interassay variabilities 9% and 5%, respectively.

Statistical analysis.   Results are presented as mean value ± SD. The patients were divided into two groups according to cardiac rhythm: sinus rhythm (group 1) and A-Fib (group 2). Differences were also tested between lone (primary) and secondary (to mitral regurgitation or LV dysfunction) A-Fib. Group comparisons were performed using a standard t test or chi-square test and comparison was also stratified according to underlying cardiac disease using analysis of variance (ANOVA). Linear and nonparametric regression was used as appropriate with N-ANP and BNP levels as the dependent variables and age, gender, presence of A-Fib, NYHA class of symptoms, LV EF, LA and right atrial volumes, cardiac index, systolic pulmonary artery pressure and endothelin-1 measurements as independent variables. Correlations were also analyzed separately in each group. Multivariate analysis using stepwise multiple linear regression was performed using the listed variables as candidates to define the independent determinants of the hormonal levels and was repeated with and without inclusion of the control patients; p < 0.05 was considered significant.

	Results

Top Abstract Methods Results Discussion Conclusions References

 
Baseline characteristics.   Among the 100 patients, atrial overload was due to organic mitral regurgitation in 58 (regurgitant volume = 74 ± 36 ml, LA volume = 122 ± 60 ml, 49 in sinus rhythm), to LV dysfunction in 24 (EF = 33 ± 8%, LA volume = 112 ± 61 ml, 19 in sinus rhythm) and to lone A-Fib in 18 (EF = 59 ± 7%, LA volume = 106 ± 44 ml). By design, there was no difference in age (p = 0.6) and gender (percentage of women: 37% vs. 43%, p = 0.67) between patients and control subjects. As shown in Table 1 (left part), in comparison to control subjects, the patients showed signs of atrial overload, with significantly higher LA and right atrial volumes, and altered hemodynamics, with reduced cardiac index and higher pulmonary pressure. The difference in LV EF was of borderline significance. The atrial overload was due partly to the high regurgitant volume (50 ± 44 vs. 4 ± 3 ml per beat, p < 0.0001) and fraction (35 ± 21% vs. 4 ± 3%, p < 0.0001) measured in patients, as compared with control subjects. Accordingly, the hormonal measurements showed that N-ANP and BNP levels in patients were significantly and considerably higher than in control subjects. However, no difference was observed for endothelin-1 levels.

Within group 2, patients with lone A-Fib (primary, n = 18) in comparison to those with secondary A-Fib (with organic disease, n = 14) had a lower BNP level (106 ± 94 vs. 240 ± 202 pg/ml, p = 0.035) but a similar N-ANP level (2,339 ± 1,542 vs. 2,968 ± 1,841 pg/ml, p = 0.30). There was a trend, albeit not significant, toward a negative association between duration of A-Fib and levels of N-ANP (r = –0.34, p = 0.06) and BNP (p = 0.20).

Determinants of natriuretic peptide levels.   In the overall population of patients and control subjects, the correlation observed between LV EF and BNP (r = –0.62, p < 0.0001) was maintained in patients with A-Fib (r = –0.51, p < 0.003), whereas that with N-ANP was weak (r = –0.22, p = 0.017) and was observed only in those in sinus rhythm (r = –0.31, p = 0.005) but not in A-Fib (r = 0.04, p = 0.81). A significant correlation was also observed between NYHA class of symptoms and N-ANP level (r = 0.42, p < 0.0001) without interaction with the presence or absence of A-Fib (p for interaction = 0.36). Stratified by symptom category, the N-ANP level was higher in patients with A-Fib than in those with sinus rhythm (adjusted p in ANOVA = 0.0004, Fig. 1). Similarly, a significant correlation was observed between NYHA class of symptoms and BNP level (r = 0.55, p < 0.0001) without interaction with the presence or absence of A-Fib (p for interaction = 0.20). Stratified by symptom category, the BNP level was not different between patients with A-Fib and those with sinus rhythm (adjusted p in ANOVA = 0.59, Fig. 2). No other variable demonstrated correlations with N-ANP level with r 0.40 in sinus rhythm or in A-Fib. Conversely, BNP correlated significantly with systolic pulmonary artery pressure (r = 0.53, p < 0.0001) and LA volume (r = 0.53, p < 0.0001).

View larger version (38K): [in this window] [in a new window]   Figure 1 N-ANP levels in patients stratified by heart failure functional class according to NYHA class I, II, and III or IV. In each class, the left bar represents patients with sinus rhythm (SR) and the right bar, patients with A-Fib. Bar height represents the mean value; the mean ± SD is indicated in each bar. The p values are those noted in the two-way ANOVA.

View larger version (33K): [in this window] [in a new window]   Figure 2 BNP levels in patients stratified by heart failure functional class according to NYHA class I, II, and III or IV. In each class, the left bar represents patients in sinus rhythm (SR) and the right bar, patients in A-Fib. Bar height represents the mean value; the mean ± SD is indicated in each bar. The p values are those noted in the two-way ANOVA.

The results of multivariate analysis are presented in Table 2. The independent determinants of higher N-ANP levels were higher NYHA functional class, A-Fib and a higher endothelin-1 level. This result was not altered if the control subjects were removed from the model (p = 0.0001, 0.0016 and 0.023, respectively). Conversely, the independent determinants of higher BNP levels were lower LV EF and higher LA volume, systolic pulmonary artery pressure and endothelin-1 level. This result was not altered after removal of the control subjects from the model (p = 0.0001, 0.00001, 0.03 and 0.008, respectively).

	Discussion

Top Abstract Methods Results Discussion Conclusions References

A-Fib and natriuretic peptides.   Atrial fibrillation is a frequent disease, particularly in the elderly (19). The prognosis of A-Fib is linked to that of the causal disease, usually benign in young patients with lone A-Fib (33), but more often associated in the elderly with relatively high rates of complications, including embolism and heart failure (19). The progressive LA enlargement observed in patients with A-Fib (34) may be partly responsible for these complications. These morphologic alterations also raise the question that A-Fib may be associated with activation of natriuretic peptides. Although the exact trigger for release of natriuretic peptides is still debated, experimental and clinical studies have suggested that atrial volume, pressure and wall stretch are the main determinants of the activation of these peptides and are all potentially altered in A-Fib (1,18,35–37).

Previous studies in small series of patients with A-Fib reported increased levels of the short half-life peptide C-terminal ANP, reflective of the instantaneous activation of ANP (21,38). This activation was not consistently observed (39) and may have been the result of associated heart diseases (mitral stenosis, cardiomyopathy) or altered hemodynamics (22,24,25,40). Little information is available about the longer half-life peptide N-ANP (22,23) or BNP levels (17), and no concomitant information on cardiac function (particularly LA volume [34] and LV function [22]) has been reported. Therefore, the respective role of A-Fib or the underlying cardiac alterations in the potential activation of natriuretic peptides is unclear.

To address these unresolved issues, the present study was designed to compare patients with A-Fib to patients with sinus rhythm with similar cardiac alterations, as determined by an extensive Doppler-echocardiographic assessment. Consequently, patients with sinus rhythm or A-Fib had very similar baseline characteristics, in particular for LA volume, EF and pulmonary pressure but also for symptoms, comorbid conditions and treatment. Using this population, we observed that chronic A-Fib is independently associated with higher N-ANP levels, which, therefore, are not confined to acute A-Fib (23) or A-Fib associated with heart failure (22). This univariate association was confirmed in comparisons stratified to the causal cardiac disease and in multivariate analysis adjusting for baseline determinants of N-ANP, in particular, symptoms and EF. Conversely, despite the association between BNP level and LA volume observed in the present study, there was no independent association of BNP level with A-Fib (17). These results were confirmed after adjustment for the level of endothelin-1, which may stimulate natriuretic peptide secretion independently of hemodynamic alterations (41). These results were also confirmed in lone A-Fib, which is associated with less hemodynamic alteration than secondary A-Fib. In lone A-Fib compared with secondary A-Fib, the N-ANP levels were not significantly different, but the BNP levels were significantly lower. These data confirm that BNP secretion closely reflects hemodynamic alterations (42), but also that any form of A-Fib even without heart failure can lead to high N-ANP levels.

The mechanism of increased N-ANP levels in A-Fib is unknown. Experimental and clinical studies have suggested that in failing myocardium, ANP secretion increases because of the up-regulation of ANP gene expression linked to the hypertrophic process (43–45). The hypothesis of an intrinsic atrial myocardial failure associated with A-Fib is consistent with our observation of no significant correlation between the hemodynamic status and the N-ANP level in patients with A-Fib and is supported by recent histologic data suggesting that A-Fib presents as an isolated atrial cardiomyopathy (46,47). The decrease of natriuretic peptides observed after cardioversion (20,24,25) does not rule out the possibility of intrinsic atrial myocardial alteration and may reflect transient inhibition of ANP secretion, as suggested by the trend for delayed recurrent increase in ANP (20) and by the inhibition of secretion also observed after the Maze procedure (48). Another possible link between A-Fib and excess ANP secretion is through G-protein alterations. As recently demonstrated, G-proteins, which form the switchboard between a family of receptors and intracellular effector molecules, mediate ANP secretion (49) and ion channel regulation (50) and, thus, may influence electrical stability of the myocyte membrane and have a role in generating A-Fib.

Clinical implications.   Clinically, the independent association between A-Fib and N-ANP level raises the question of the role of N-ANP level in prognostic stratification. In CHF and ischemic heart disease, higher N-ANP levels are associated with worse outcome (6,7). Although the N-ANP level in A-Fib is not acutely predictive of return to sinus rhythm (23), its large individual variation suggests a potential role as a prognostic indicator that should be evaluated in large long-term studies.

Another important clinical issue is the use of natriuretic peptides as diagnostic markers for LV dysfunction. Congestive heart failure is the source of high morbidity and mortality (9) and is due most often to LV dysfunction (10). Recognizing LV dysfunction before overt failure is challenging but may allow early treatment (10). Previous studies demonstrated that ANP levels are increased in patients with CHF (3) proportionally to the degree of hemodynamic alteration (2,5). Therefore, several studies have attempted to define the role of natriuretic peptides as markers of LV dysfunction, with or without symptoms (11,13–15). Although all studies found significant diagnostic value of natriuretic peptides as markers of LV dysfunction (11,13–15), some inconsistencies were observed, suggesting that either N-ANP (13) or BNP (14,15) had a superior diagnostic accuracy. These discrepancies suggest that the diagnostic value of natriuretic peptides for LV dysfunction is dependent on the population in which it is applied. This is particularly relevant in the elderly, in whom many interactions are possible (17) and in whom both heart failure and A-Fib are particularly frequent (19). Although our data confirmed a correlation between N-ANP level and LV EF (11), the observation that N-ANP is strongly influenced by A-Fib (40) limits the value of this peptide as a marker of LV dysfunction. This observation is consistent with the most recent large cohort series, which observed a relatively low specificity of N-ANP (14,15). Conversely, BNP is not independently influenced by A-Fib and shows a strong correlation with EF, even in this population with atrial overload, which is a potential explanation for its high sensitivity and specificity as a diagnostic marker for LV dysfunction (14,15).

Study limitations.   Analysis of the diagnostic value or of all possible hemodynamic determinants of natriuretic peptides would require very large sample sizes, which could not be achieved in a prospective study concomitantly with extensive Doppler echocardiographic assessment. However, these were not the goals of the study, and appropriate adjustment for major hemodynamic variables, comorbid conditions, treatment and other hormonal alterations could be achieved to analyze the independent effect of A-Fib on natriuretic peptides (21). Left atrial overload was specifically analyzed by measuring atrial volume, which reflects atrial remodeling (34) better than the M-mode atrial size used in previous studies (21). By using patients in sinus rhythm with atrial overload for comparison, the bias of major differences in cardiac status observed between patients with sinus rhythm and those with A-Fib was avoided, and most baseline characteristics were identical between the two groups, which is a unique feature of the present study. Right atrial volume was also measured and significant differences were observed between patients with A-Fib and those in sinus rhythm, but because of the wide range of values, these differences could be adjusted for in multivariate analysis. Therefore, these differences do not alter the conclusions of the study regarding the associations of A-Fib with natriuretic peptides.

The control population was referred to the echocardiography laboratory, and bias may be a concern. However, the N-ANP levels were very similar to those obtained in population-based studies (23) and the echocardiographic measurements were similar to those defined by the American Society of Echocardiography (32), in agreement with an appropriate control population.

Although the present study was not designed to address the molecular mechanism of activation of ANP in patients with A-Fib, it could analyze the relationship of natriuretic peptide activation with hemodynamic alterations, atrial overload and LV function. Future experimental and human studies should explore these mechanistic issues as well as the prognostic impact of this association.

	Conclusions

Top Abstract Methods Results Discussion Conclusions References

 
Comparison of patients with A-Fib to patients with sinus rhythm with similar clinical characteristics, LA overload, LV EF and filling characteristics, pulmonary pressure and endothelin-1 level showed that A-Fib is independently associated with a higher N-ANP level and blurs the association of N-ANP with reduced LV function. Conversely, the BNP level is not independently affected by A-Fib and remains strongly associated with LV dysfunction, for which it can be used as a marker both in sinus rhythm and A-Fib.

	Footnotes

 
This study was funded by the Mayo Foundation.

	References

Top Abstract Methods Results Discussion Conclusions References

 

1. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321–328[Free Full Text]
2. Burnett JC Jr, Kao PC, Hu DC, et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science. 1986;231:1145–1147[Abstract/Free Full Text]
3. Raine AE, Erne P, Burgisser E, et al. Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N Engl J Med. 1986;315:533–537[Abstract]
4. Benedict CR, Johnstone DE, Weiner DH, et al. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1994;23:1410–1420[Abstract]
5. Wei CM, Heublein DM, Perrella MA, et al. Natriuretic peptide system in human heart failure. Circulation. 1993;88:1004–1009[Abstract/Free Full Text]
6. Hall C, Rouleau JL, Moye L, et al. N-terminal proatrial natriuretic factor: an independent predictor of long-term prognosis after myocardial infarction. Circulation. 1994;89:1934–1942[Abstract/Free Full Text]
7. Dickstein K, Aarsland T, Hall C. Plasma N-terminal atrial natriuretic factor: a predictor of survival in patients with congestive heart failure. J Card Fail. 1997;3:83–89[CrossRef][Medline]
8. Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol. 1992;20:301–306[Abstract]
9. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993;88:107–115[Abstract/Free Full Text]
10. Cohn JN. The management of chronic heart failure. N Engl J Med. 1996;335:490–498[Free Full Text]
11. Lerman A, Gibbons RJ, Rodeheffer RJ, et al. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet. 1993;341:1105–1109[CrossRef][Medline]
12. Thibault G, Murthy KK, Gutkowska J, et al. NH2-terminal fragment of rat pro-atrial natriuretic factor in the circulation: identification, radioimmunoassay and half-life. Peptides. 1988;9:47–53[CrossRef][Medline]
13. Muders F, Kromer EP, Griese DP, et al. Evaluation of plasma natriuretic peptides as markers for left ventricular dysfunction. Am Heart J. 1997;134:442–449[CrossRef][Medline]
14. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997;350:1349–1353[CrossRef][Medline]
15. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet. 1998;351:9–13[CrossRef][Medline]
16. Tan LB, Hall A. Diagnosis of symptomless left ventricular dysfunction. (letter to the editor)Lancet. 1993;342:116–117[CrossRef][Medline]
17. Wallen T, Landahl S, Hedner T, Saito Y, Masuda I, Nakao K. Brain natriuretic peptide in an elderly population. J Intern Med. 1997;242:307–311[CrossRef][Medline]
18. Globits S, Frank H, Pacher B, Huelsmann M, Ogris E, Pacher R. Atrial natriuretic peptide release is more dependent on atrial filling volume than on filling pressure in chronic congestive heart failure. Am Heart J. 1998;135:592–597[CrossRef][Medline]
19. Narayan SM, Cain ME, Smith JM. Atrial fibrillation. Lancet. 1997;350:943–950[CrossRef][Medline]
20. Petersen P, Kastrup J, Vilhelmsen R, Schutten HJ. Atrial natriuretic peptide in atrial fibrillation before and after electrical cardioversion therapy. Eur Heart J. 1988;9:639–641[Abstract/Free Full Text]
21. Berglund H, Boukter S, Theodorsson E, Vallin H, Edhag O. Raised plasma concentrations of atrial natriuretic peptide are independent of left atrial dimensions in patients with chronic atrial fibrillation. Br Heart J. 1990;64:9–13[Abstract/Free Full Text]
22. Tuinenburg AE, Van Veldhuisen DJ, Boomsma F, Van Den Berg MP, De Kam PJ, Crijns HJ. Comparison of plasma neurohormones in congestive heart failure patients with atrial fibrillation versus patients with sinus rhythm. Am J Cardiol. 1998;81:1207–1210[CrossRef][Medline]
23. Hornestam B, Hall C, Held P, et al. N-terminal proANF in acute atrial fibrillation: a biochemical marker of atrial pressures but not a predictor for conversion to sinus rhythm. Am Heart J. 1998;135:1040–1047[CrossRef][Medline]
24. Mookherjee S, Anderson G Jr, Smulyan H, Vardan S. Atrial natriuretic peptide response to cardioversion of atrial flutter and fibrillation and role of associated heart failure. Am J Cardiol. 1991;67:377–380[CrossRef][Medline]
25. Fujiwara H, Ishikura F, Nagata S, Beppu S, Miyatake K. Plasma atrial natriuretic peptide response to direct current cardioversion of atrial fibrillation in patients with mitral stenosis. J Am Coll Cardiol. 1993;22:575–580[Abstract]
26. Tajik AJ, Seward JB, Hagler DJ, Mair DD, Lie JT. Two-dimensional real-time ultrasonic imaging of the heart and great vessels: technique, image orientation, structure identification, and validation. Mayo Clin Proc. 1978;53:271–303[Medline]
27. Lewis JF, Kuo LC, Nelson JG, Limacher MC, Quinones MA. Pulsed Doppler echocardiographic determination of stroke volume and cardiac output: clinical validation of two new methods using the apical window. Circulation. 1984;70:425–431[Abstract/Free Full Text]
28. Rokey R, Sterling LL, Zoghbi WA, et al. Determination of regurgitant fraction in isolated mitral or aortic regurgitation by pulsed Doppler two-dimensional echocardiography. J Am Coll Cardiol. 1986;7:1273–1278[Abstract]
29. Enriquez-Sarano M, Miller FA Jr, Hayes SN, Bailey KR, Tajik AJ, Seward JB. Effective mitral regurgitant orifice area: clinical use and pitfalls of the proximal isovelocity surface area method. J Am Coll Cardiol. 1995;25:703–709[Abstract]
30. Currie PJ, Seward JB, Chan KL, et al. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol. 1985;6:750–756[Abstract]
31. Kircher B, Abbott JA, Pau S, et al. Left atrial volume determination by biplane two-dimensional echocardiography: validation by cine computed tomography. Am Heart J. 1991;121:864–871[CrossRef][Medline]
32. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr. 1989;2:358–367[Medline]
33. Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history of lone atrial fibrillation: a population-based study over three decades. N Engl J Med. 1987;317:669–674[Abstract]
34. Sanfilippo AJ, Abascal VM, Sheehan M, et al. Atrial enlargement as a consequence of atrial fibrillation: a prospective echocardiographic study. Circulation. 1990;82:792–797[Abstract/Free Full Text]
35. Rodeheffer RJ, Tanaka I, Imada T, Hollister AS, Robertson D, Inagami T. Atrial pressure and secretion of atrial natriuretic factor into the human central circulation. J Am Coll Cardiol. 1986;8:18–26[Abstract]
36. Edwards BS, Zimmerman RS, Schwab TR, Heublein DM, Burnett JC Jr. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res. 1988;62:191–195[Abstract/Free Full Text]
37. Brookes CI, Kemp MW, Hooper J, Oldershaw PJ, Moat NE. Plasma brain natriuretic peptide concentrations in patients with chronic mitral regurgitation. J Heart Valve Dis. 1997;6:608–612[Medline]
38. Roy D, Paillard F, Cassidy D, et al. Atrial natriuretic factor during atrial fibrillation and supraventricular tachycardia. J Am Coll Cardiol. 1987;9:509–514[Abstract]
39. Theodorakis GN, Markianos M, Kouroubetsis CK, Livanis EG, Paraskevaidis IA, Kremastinos DT. Clinical, adrenergic and heart endocrine measures in chronic atrial fibrillation as predictors of conversion and maintenance of sinus rhythm after direct current cardioversion. Eur Heart J. 1996;17:550–556[Abstract/Free Full Text]
40. Dussaule JC, Vahanian A, Michel PL, et al. Plasma atrial natriuretic factor and cyclic GMP in mitral stenosis treated by balloon valvulotomy: effect of atrial fibrillation. Circulation. 1988;78:276–285[Abstract/Free Full Text]
41. Uusimaa PA, Hassinen IE, Vuolteenaho O, Ruskoaho H. Endothelin-induced atrial natriuretic peptide release from cultured neonatal cardiac myocytes: the role of extracellular calcium and protein kinase-C. Endocrinology. 1992;130:2455–2464[Abstract]
42. Luchner A, Stevens TL, Borgeson DD, et al. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol. 1998;274:H1684–H1689
43. Saito Y, Nakao K, Arai H, et al. Augmented expression of atrial natriuretic polypeptide gene in ventricle of human failing heart. J Clin Invest. 1989;83:298–305[Medline]
44. Boluyt MO, O’Neill L, Meredith AL, et al. Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure: marked upregulation of genes encoding extracellular matrix components. Circ Res. 1994;75:23–32[Abstract/Free Full Text]
45. Lloyd MA, Grogan M, Sandberg SM, et al. Presence of atrial natriuretic factor in ventricular tissue in tachycardia-induced cardiomyopathy. Am J Cardiol. 1994;73:984–986[CrossRef][Medline]
46. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997;96:1180–1184[Abstract/Free Full Text]
47. Ausma J, Wijffels M, Thone F, Wouters L, Allessie M, Borgers M. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation. 1997;96:3157–3163[Abstract/Free Full Text]
48. Kim KB, Lee CH, Kim CH, Cha YJ. Effect of the Cox maze procedure on the secretion of atrial natriuretic peptide. J Thorac Cardiovasc Surg. 1998;115:139–146[Abstract/Free Full Text]
49. Meij JT. Regulation of G protein function: implications for heart disease. Mol Cell Biochem. 1996;157:31–38[Medline]
50. Wickman KD, Clapham DE. G-protein regulation of ion channels. Curr Opin Neurobiol. 1995;5:278–285[CrossRef][Medline]

This article has been cited by other articles:

				F. Sacher, J.-B. Corcuff, P. Schraub, V. Le Bouffos, A. Georges, S. O. Jones, S. Lafitte, P. Bordachar, M. Hocini, J. Clementy, et al. Chronic atrial fibrillation ablation impact on endocrine and mechanical cardiac functions Eur. Heart J., May 2, 2008; 29(10): 1290 - 1295. [Abstract] [Full Text] [PDF]

				S. Dinanian, C. Boixel, C. Juin, J.-S. Hulot, A. Coulombe, C. Rucker-Martin, N. Bonnet, B. Le Grand, M. Slama, J.-J. Mercadier, et al. Downregulation of the calcium current in human right atrial myocytes from patients in sinus rhythm but with a high risk of atrial fibrillation Eur. Heart J., May 1, 2008; 29(9): 1190 - 1197. [Abstract] [Full Text] [PDF]

				P. Kirchhof, A. Auricchio, J. Bax, H. Crijns, J. Camm, H.-C. Diener, A. Goette, G. Hindricks, S. Hohnloser, L. Kappenberger, et al. Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association Europace, November 1, 2007; 9(11): 1006 - 1023. [Abstract] [Full Text] [PDF]

				A. Rossi, M. Cicoira, S. Bonapace, G. Golia, L. Zanolla, L. Franceschini, and C. Vassanelli Left atrial volume provides independent and incremental information compared with exercise tolerance parameters in patients with heart failure and left ventricular systolic dysfunction Heart, November 1, 2007; 93(11): 1420 - 1425. [Abstract] [Full Text] [PDF]

				T. Yamada, Y. Murakami, T. Okada, N. Yoshida, J. Toyama, Y. Yoshida, N. Tsuboi, Y. Inden, M. Hirai, and T. Murohara Plasma brain natriuretic peptide level after radiofrequency catheter ablation of paroxysmal, persistent, and permanent atrial fibrillation Europace, September 1, 2007; 9(9): 770 - 774. [Abstract] [Full Text] [PDF]

				W.H. Wilson Tang, G. S. Francis, D. A. Morrow, L. K. Newby, C. P. Cannon, R. L. Jesse, A. B. Storrow, R. H. Christenson, COMMITTEE MEMBERS, R. H. Christenson, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure Circulation, July 31, 2007; 116(5): e99 - e109. [Full Text] [PDF]

				T Date, T Yamane, K Inada, S Matsuo, S Miyanaga, K Sugimoto, K Shibayama, I Taniguchi, and S Mochizuki Plasma brain natriuretic peptide concentrations in patients undergoing pulmonary vein isolation Heart, November 1, 2006; 92(11): 1623 - 1627. [Abstract] [Full Text] [PDF]

				Writing Committee Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Europace, September 1, 2006; 8(9): 651 - 745. [Full Text] [PDF]

				V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society J. Am. Coll. Cardiol., August 15, 2006; 48(4): e149 - e246. [Full Text] [PDF]

				V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society Circulation, August 15, 2006; 114(7): e257 - e354. [Full Text] [PDF]

				M. Rienstra, I. C. Van Gelder, M. P. Van den Berg, F. Boomsma, and D. J. Van Veldhuisen Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-)ANP and (NT-pro)BNP Europace, July 1, 2006; 8(7): 482 - 487. [Abstract] [Full Text] [PDF]

				C. A. Dezsi, A. Szucs, G. Szucs, A. Roka, O. Kiss, D. Becker, and B. Merkely Short-term effect of rate control on plasma endothelin levels of patients with tachyarrhythmias. Experimental Biology and Medicine, June 1, 2006; 231(6): 852 - 856. [Abstract] [Full Text] [PDF]

				J. A. Laukkanen, S. Kurl, M. Ala-Kopsala, O. Vuolteenaho, H. Ruskoaho, K. Nyyssonen, and J. T. Salonen Plasma N-terminal fragments of natriuretic propeptides predict the risk of cardiovascular events and mortality in middle-aged men Eur. Heart J., May 2, 2006; 27(10): 1230 - 1237. [Abstract] [Full Text] [PDF]

				J. Cosgrave, J. B. Foley, E. McGovern, K. Bennett, V. Young, M. Tolan, P. Crean, and M. Walsh Brain natriuretic peptide elevation and the development of atrial fibrillation following coronary artery bypass surgery Interactive CardioVascular and Thoracic Surgery, April 1, 2006; 5(2): 111 - 114. [Abstract] [Full Text] [PDF]

				P. T. Ellinor, A. F. Low, and C. A. MacRae Reduced apelin levels in lone atrial fibrillation Eur. Heart J., January 2, 2006; 27(2): 222 - 226. [Abstract] [Full Text] [PDF]